Within this frame, attempts have been made to use peptide vaccines targeted mainly at the stimulation of tumor-specific Major Histocompatibility Complex (MHC) class I-restricted CD8+ cytotoxic T lymphocytes (CTL), the major effectors of anti-tumor responses (14). The gene discussed is CD8A; the disease is neoplasm.